Completed
PHASE3
INTERVENTIONAL
NCT05394519
A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
This study will look at how well the new medicine CagriSema helps people living with excess body weight and type 2 diabetes losing weight. Participants will either get CagriSema or a dummy medicine. Which treatment they get is decided by chance. The study will last for about 1½ years. Women cannot take part if pregnant, breast-feeding or planning to get pregnant during the study period.
Interventions
Name:
Cagrilintide
Type:
DRUG
Description:
Cagrilintide administered subcutaneously (s.c., under the skin) once-weekly
Name:
Semaglutide
Type:
DRUG
Description:
Semaglutide administered subcutaneously (s.c., under the skin) once-weekly
Name:
Placebo cagrilintide
Type:
DRUG
Description:
Placebo cagrilintide administered subcutaneously (s.c., under the skin) once-weekly
Name:
Placebo semaglutide
Type:
DRUG
Description:
Placebo semaglutide administered subcutaneously (s.c., under the skin) once-weekly
Primary Outcomes
Measure:
Relative change in body weight
TimeFrame:
From baseline (week 0) to end of treatment (week 68)
Description:
Measured in percentage (%).
Measure:
Achievement of greater than or equal to (≥) 5% weight reduction
TimeFrame:
From baseline (week 0) to end of treatment (week 68)
Description:
Count of participant.
Trial Information
NCT ID
NCT05394519
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE3
Sponsor
Novo Nordisk A/S
Last Updated
December 15, 2025